Investment Thesis
Caribou Biosciences is a pre-revenue clinical-stage biotech company with severe operating losses and massive cash burn that far exceeds revenue generation. With only $12.4M in cash against $111M annual operating cash burn, the company faces critical liquidity constraints and will require significant capital raises or major clinical success to avoid financial distress within 12 months.
Strengths
- Strong balance sheet with $122.2M stockholders equity provides substantial capital base
- Excellent liquidity position with 5.71x current ratio indicating near-term payment capability
- Zero long-term debt eliminates refinancing risk and interest burden
- Revenue growth of 11.7% YoY shows emerging commercial activity from R&D programs
Risks
- Catastrophic cash burn of $111M annually against only $12.4M cash reserves indicates 1.3 months of runway at current burn rate
- Operating losses of $148.3M on $11.2M revenue demonstrates completely unprofitable operations with losses 1,329% of revenue
- Pre-commercial biotech model creates absolute dependence on clinical trial success and future funding; single negative trial result could be fatal
- Negative free cash flow of $112.4M combined with minimal revenue makes the company entirely dependent on capital markets for survival
- High insider trading activity (14 Form 4 filings in 90 days) may indicate uncertainty or management exit timing concerns
Key Metrics to Watch
- Cash position and runway until next financing required
- Clinical trial progress and regulatory milestones for lead programs
- Monthly cash burn rate and achievement of operational cost reduction targets
- Ability to secure funding and terms of future capital raises
- Revenue growth trajectory from commercialization efforts
Financial Metrics
Revenue
11.2M
Net Income
-148.1M
EPS (Diluted)
$-1.59
Free Cash Flow
-112.4M
Total Assets
175.4M
Cash
12.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,329.4%
Net Margin
-1,327.4%
ROE
-121.2%
ROA
-84.5%
FCF Margin
-1,006.8%
Balance Sheet & Liquidity
Current Ratio
5.71x
Quick Ratio
5.71x
Debt/Equity
0.00x
Debt/Assets
30.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T22:56:12.261844 |
Data as of: 2025-12-31 |
Powered by Claude AI